Theoretical Basis for the EDA Concept - Good Cascade Impactor Practices, AIM and EDA for Orally Inhaled Products - page 165

10. Newman SP, Wilding IR, Hirst PH (2000) Human lung deposition data: the bridge between
in vitro and clinical evaluations for inhaled drug products? Int J Pharm 208:49-60
11. Tougas TP, Christopher D, Mitchell JP, Strickland H, Wyka B, Van Oort M, Lyapustina S
(2009) Improved quality control metrics for cascade impaction measurements of orally inhaled
drug products (OIPs). AAPS PharmSciTech 10(4):1276-1285
12. Wheeler DJ (2006) EMP (evaluating the measurement process) III: using imperfect data. SPC,
Knoxville, TN
13. AIAG (Automotive Industry Action Group) (2010) Measurement system analysis, reference
manual, 4th edn. AIAG, Southfield, MI, USA, ISBN#: 978-1-60-534211-5
14. Bower KM, Touchton ME (2001) Evaluating the usefulness of data by gage repeatability and
reproducibility. Asia Pacific Process Engineer. http://www.minitab.com/en-US/training/
articles/default.aspx . Accessed 22 July 2012
15. Tougas TP (2006) Considerations of the role of end product testing in assuring the quality of
pharmaceutical products. Process Anal Technol 3:13-17
16. Summers DCS (1997) Quality. Prentice Hall, Upper Saddle River, NJ
17. Dunbar C, Mitchell JP (2005) Analysis of cascade impactor mass distributions. J Aerosol Med
18(4):439-451
18. Marple VA, Roberts DL, Romay FJ, Miller NC, Truman KG, Van Oort M, Olsson B, Holroyd
MJ, Mitchell JP, Hochrainer D (2003) Next generation pharmaceutical impactor. Part 1:
Design. J Aerosol Med 16:283-299
19. Mitchell JP, Nagel MW (2003) Cascade impactors for the size characterization of aerosols
from medical inhalers; their uses and limitations. J Aerosol Med 16:341-376
20. O'Shaughnessy PT, Raabe OG (2003) A comparison of cascade impactor data reduction meth-
ods. Aerosol Sci Technol 37(2):187-200
21. US Food and Drug Administration (FDA) (1998) CDER. Draft guidance for industry metered
dose inhaler (MDI) and dry powder inhaler (DPI) drug products chemistry, manufacturing, and
controls documentation, Rockville, MD, USA. http://www.fda.gov/cder/guidance/2180dft.
pdf . Accessed 15 July 2012
22. European Medicines Agency (EMA) (2006) Guideline on the pharmaceutical quality of inha-
lation and nasal products. London, UK, EMEA/CHMP/QWP/49313/2005 Final. http://www.
ema.europa.eu/pdfs/human/qwp/4931305en.pdf . Accessed 20 Jan 2012
23. Health Canada (2006) Guidance for industry: pharmaceutical quality of inhalation and nasal
products. File Number file number: 06-106624-547. http://www.hc-sc.gc.ca/dhp-mps/alt_
formats/hpfb-dgpsa/pdf/prodpharma/inhalationnas-eng.pdf . Accessed 20 Jan 2012
24. Hinds WC (1999) Aerosol technology: properties, behavior, and measurement of airborne par-
ticles, 2nd edn. John Wiley & Sons, New York